Group 1 - The core stock price of Beilu Pharmaceutical (300016) closed at 9.44 yuan on January 12, 2026, with an increase of 2.39% and a turnover rate of 8.34%, resulting in a trading volume of 469,100 shares and a transaction amount of 439 million yuan [1] - The company reported significant revenue growth from its export products, primarily contrast agents and raw materials, covering markets in South America, Africa, and Asia [2] - The overall gross margin for the company's overseas business in 2024 was only 17.57%, significantly lower than the disclosed gross margin of 49.2% for contrast agents, attributed to a higher proportion of raw materials in the export revenue structure [2] Group 2 - On January 12, the net inflow of main funds into Beilu Pharmaceutical was 7.25 million yuan, indicating positive engagement from major investors [3] - The net inflow of speculative funds was 4.87 million yuan, while retail investors experienced a net outflow of 12.12 million yuan [4]

Group 1 - The core point of the article is that Beilu Pharmaceutical (300016) holds a 14.9881% stake in Yiwei Medical, making it the second-largest shareholder [1] Group 2 - Beilu Pharmaceutical's investment in Yiwei Medical indicates a strategic positioning within the healthcare sector [1] - The interaction with investors highlights the company's transparency and engagement in shareholder communication [1]

Group 1 - The core viewpoint of the article is that Beilu Pharmaceutical holds a significant stake in Yiwei Medical, which is a leading AI company in China focused on brain diseases, covering the entire process from screening to diagnosis and rehabilitation [1] - Beilu Pharmaceutical currently owns 14.9881% of Yiwei Medical, making it the second-largest shareholder [1] - Yiwei Medical specializes in non-invasive brain-machine interfaces, neuroregulation, and medical AI, targeting essential scenarios such as stroke, Alzheimer's disease, and cognitive disorders [1]

证券日报网讯 1月8日，北陆药业发布公告称，公司2026年第一次临时股东会审议通过《关于前次募集 资金使用情况报告的议案》等。 （文章来源：证券日报） ...

法律意见书 即其已提供了本所律师认为作为出具本法律意见书所必需的材料，所提供的原始 材料、副本、复印件等材料、口头证言均符合真实、准确、完整的要求，有关副 本、复印件等材料与原始材料一致。 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席本次 股东会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》等法 律、法规、规范性文件及《公司章程》的规定发表意见，不对会议审议的议案内 容以及该等议案所表述的事实或数据的真实性及准确性发表意见。本所经办律师 无法对网络投票股东资格进行核查，在参与网络投票的股东资格均符合《公司法》 等相关法律、行政法规、规范性文件及《公司章程》规定的前提下，相关出席会 议股东符合资格。 北京市中伦律师事务所 关于北京北陆药业股份有限公司 2026 年第一次临时股东会的 法律意见书 致：北京北陆药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为北京北陆药业股份有限公 司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2026 年第一次临时股东会（以下简称"本次股东会"）。本所律师根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中 ...

股票代码：300016 股票简称：北陆药业 公告编号：2026-002 北京北陆药业股份有限公司 2026年第一次临时股东会决议公告 特别提示： 1、本次股东会无增加、变更、否决提案的情况； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开的日期和时间： （1）现场会议召开时间为：2026年1月8日（星期四）下午14：30 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具 体时间为2026年1月8日9：15—9：25、9：30—11：30、13：00—15：00；通 过深圳证券交易所互联网投票系统投票的时间为2026年1月8日上午9：15至下 午15：00期间的任意时间。 2、召开地点：北京市海淀区西直门北大街 32 号枫蓝国际写字楼 A 座 7 层 A1 会议室 3、会议召集人：公司董事会 4、会议主持人：董事长、总经理 王旭 1 5、召开方式：本次会议采取现场投票和网络投票相结合的方式 6、会议召开的合法、合规性：公司第九届董事会第七次会议审议通过了 《关 ...

Group 1 - The brain-computer interface concept has seen a rise of 3.27%, ranking 9th among concept sectors, with 56 stocks increasing in value [1] - Notable stocks that reached the daily limit include Kangtong Medical, Aipeng Medical, and Puni Testing, all achieving a 20% increase, while Nanjing Panda, Pulit, and Innovation Medical also hit the limit [1] - Leading gainers in the sector include Kefu Medical, Yinkang Life, and Danghong Technology, with increases of 13.52%, 7.39%, and 6.67% respectively [1] Group 2 - The brain-computer interface sector attracted a net inflow of 1.115 billion yuan, with 41 stocks receiving net inflows, and 9 stocks exceeding 100 million yuan in net inflow [2] - The top stock for net inflow is Yanshan Technology, with a net inflow of 974 million yuan, followed by Seli Medical, Hainan Haiyao, and Aipeng Medical with net inflows of 314 million yuan, 272 million yuan, and 237 million yuan respectively [2] Group 3 - In terms of net inflow ratio, Innovation Medical, Seli Medical, and Beilu Pharmaceutical lead with ratios of 51.56%, 17.45%, and 16.93% respectively [3] - The brain-computer interface sector's top stocks by net inflow include Yanshan Technology with a 9.96% increase and a turnover rate of 34%, and Seli Medical with a 9.98% increase and a turnover rate of 33.31% [3][4]

证券日报网讯 1月7日，北陆药业发布公告称，公司将于2026年1月8日召开2026年第一次临时股东会。 （文章来源：证券日报） ...

股票代码：300016 股票简称：北陆药业 公告编号：2026-001 北京北陆药业股份有限公司 关于召开2026年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于2025年12月24日在 巨潮资讯网发布了《关于召开2026年第一次临时股东会的通知》，为进一步 保护投资者的合法权益，方便公司股东行使股东会表决权，现将股东会的有 关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：公司第九届董事会第七次会议审议通过了 《关于召开2026年第一次临时股东会的议案》，本次股东会会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议时间： （1）现场会议时间：2026年01月08日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为2026年01月08日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所 互联网 ...

Group 1 - The chemical pharmaceutical sector increased by 3.63% on January 5, with Frontier Biotech leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable stock performances included Frontier Biotech with a closing price of 21.20, up 17.45%, and Beilu Pharmaceutical at 66.8, up 13.22% [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 716 million yuan from institutional investors, while retail investors contributed a net inflow of 131 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 17.4 million yuan and ST Renfu with 9.15 million yuan [3] - Conversely, stocks like ST Jinfeng and Kangzhiyue experienced net outflows of 6.90 million yuan and 11.61 million yuan respectively [2][3]